On­colyt­ic virus ex­perts at Replimune re­load with $200M loan as biotech col­lects clin­i­cal da­ta

A gen­er­al­ly gloomy pub­lic mar­ket hasn’t stopped biotechs with big clin­i­cal plans from rak­ing in the cash — ei­ther through stock of­fer­ings or loans.

Replimune is …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER